1. In Vivo
  2. >>Business Strategy

The GSK/Pfizer HIV Venture: Another Sign of Change?

Pfizer and GSK inked an innovative deal to create a jointly owned company focused on HIV therapeutics. The marriage combines GSK's marketing muscle and a stable of established products with Pfizer's newer offerings. While it's unlikely the new venture will unseat rival Gilead as the top player in the HIV market, the deal could be a cash cow for both drug makers, especially if a spin-out ensues.

Just one week after announcing a company-wide reorganization pending its integration of Wyeth, Pfizer Inc. was once again in the headlines--this time for an innovative deal with GlaxoSmithKline PLC to create a jointly owned company focused on HIV therapeutics. [See Deal] The marriage combines GSK’s marketing muscle and its established stable of products with Pfizer’s newer but earlier-stage offerings; GSK’s 85% equity share makes it by far the dominant partner, however. Still, by merging the pipelines and commercial infrastructures of both organizations, Pfizer and GSK create a business that is far stronger than either is capable of operating—or willing to operate--independently. HIV wasn’t a core priority for either drug company, and carving it out helps isolate some of the unwelcome controversy this therapeutic area can attract.

While it’s unlikely the new--and as yet unnamed--joint venture will unseat rival Gilead Sciences Inc. as the top player in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.